Alzheimer's Cure Index
5787 views
Rate Now: 1 2 3 4

average rating: 3.66 / 3 ratings
Created by Pam
DESCRIPTION:

Date updated:01-05-2007

One hundred years ago, Dr. Alois Alzheimer identified the ailment that bears his name. Scientists are now decoding the disease and testing drugs that could delay and maybe even cure Alzheimer's. Here are the public companies who are beind these drugs designed to treat, delay or prevent Alzheimer's.

According to a recent BusinessWeek article, "there are currently 4.5 million Alzheimer's patients in the U.S., and the direct and indirect costs of caring for them total more than $100 billion a year, making Alzheimer's the third most expensive illness after heart disease and cancer. Yet the federal government budgeted only $645 million for Alzheimer's research for 2007, $7 million less than the prior year. In contrast, $2.6 billion was allocated for research into HIV/AIDS, which afflicts one million Americans."

symbol name last price % change open
  • +
  • NRMX
    N/a
  • $2.00
  • 0.00
  • $2.00

The drug Alzhemed is being produced by Neurochem. It prevents the accumulation of amyloid, a toxic protein that destroys brain cells in Alzheimer's victims. It's in Phase 3 late stage testing. The data on Alzhemed have been promising but scant. In a 2002 study it stabilized the disease in nine patients over six months, but the small sample left plenty of specialists skeptical. A clinical trial of the drug will wrap up in January, with results expected in the spring.

People owning NRMX also tend to own: AMKRANADBDYCBAKENZFRGIOC

TheStreet.com Rating: No Rating What is this?

  • +
  • MYGN
    Myriad Genetics
  • $23.46
  • 0.00%
  • $N/A

The drug Flurizan is being produced by Myriad Genetics. It inhibits the production of amyloid. It's in Phase 3 of testing with results expected next summer.

People owning MYGN also tend to own: MIKRSWFTCPHDCRDCINFYNKTRSAY

TheStreet.com Rating: B- What is this?

  • +
  • MEMY
    N/a
  • $0.14
  • 0.00
  • $0.14

The drug MEM1003 is being produced by Memory Pharmaceuticals. It evens out the irregularities in brain levels of calcium - one of the first manifestations of Alzheimer's. It's in Phase 2 of testing.

People owning MEMY also tend to own: BIOMBLDPBMRNDJOEICUFULHWCC

TheStreet.com Rating: No Rating What is this?

  • +
  • WYE
  • $0.00
  • 0.00%
  • $N/A

The drug AAB-001 is being produced by Wyeth and Elan. It's a monoclonal antibody that seeks out and removes amyloid in the brain. It's in Phase 2 of testing.

People owning WYE also tend to own: ARXTCALPCAMH.OBFXIGSTLJTXKMP

TheStreet.com Rating: No Rating What is this?

  • +
  • LLY
    Lilly Eli Co
  • $36.12
  • -0.25%
  • $36.07

The drug LY450139 is being produced by Eli Lilly. It blocks an enzyme that snips off amyloid fragments, thus reducing the production of amyloid. It's in Phase 2 of testing.

People owning LLY also tend to own: CCLXCVSGOOGGSHDJNJ

TheStreet.com Rating: C What is this?

  • +
  • ELN
    Elan Cp Plc Adr
  • $6.64
  • -0.75%
  • $6.64

The drug ACC-101 is being produced by Elan and Wyeth. The vaccine prompts the body's immune system to attack and remove amyloid in the brain. It's in Phase 1 (early safety tests)

People owning ELN also tend to own: AMGNBWNGIASGITKG.OBBBYHOFFMOT

TheStreet.com Rating: No Rating What is this?

  • +
  • DNA
    N/a
  • $80.43
  • 0.00
  • $80.43

Nearly 60 drugs designed to modify the disease are in clinical trials. One is from AC Immune of Switzerland who recently struck a deal with biotech power player Genentech Inc. (DNA ). While known for its cancer treatments, Genentech just announced plans to invest $300 million for the rights to AC Immune's drug.

People owning DNA also tend to own: AAPLDSCMGOOGXOMDWELXGLW

TheStreet.com Rating: No Rating What is this?

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Cramer's Take on Headline Stocks...

Not a Stockpickr member? Join the community today -- for free.Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about...

11.20.09 | 11:48 AM
Jim Cramer's Portfolios of the Week

By Roberto Pedone Posted on Nov. 20, 2009 According to Jim Cramer, options expiration is driving the current market selloff. He pointed out that the only stocks that we...

11.20.09 | 08:09 AM
'Fast Money' Portfolios of the Week

By Roberto Pedone Posted on Nov. 19, 2009 According to CNBC’s “Fast Money” traders, the stock market is showing no signs of stopping its current bull run. Joe Ter...

11.19.09 | 11:13 AM
Squeezing the Shorts: Earnings G...

By Jonas Elmerraji Posted on Nov. 18, 2009 There are plenty of reasons for stocks to have the attention of short-sellers. Waning financials, a deteriorating business mo...

11.18.09 | 12:36 PM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
Wealth distribution by race and ...
11.23.08 | 18:44 PM From author Valerie J
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
more forums
Q. I am a studetn about to graduate...
11.20.09 | 23:08 PM Asked by Amanda Bowen

A. Long term investment considerations: 20%
in OIH ETF; 10% in GDX ETF and 10% in
GDXJ (Van Eck Jr Gold Mining) ETF . . .
If your grandparents were thoughtful
enough to provide you with funds to
become actively involved in the
trading/investing world, communicate
with them on a regular basis in order to
compare their point of view/insight with
other reliable sources . . . including
those reflected on Online School @
http://www.onlineschools.org/2009/10/22/
100-best-blogs-for-future-investors/
and ValueWiki @
http://blog.valuewiki.com/2007/02/26/top
-100-finance-blogs/

Be open/flexible, resourceful, and
pursue due diligence (research). Best of
luck.

today 's lists
52-Week Lows

Here is a list of some of the biggest stocks that hit 52-week lows on Nov. 20, 2009. more

Analyst Downgrades

Analyst Downgrades or Estimate Reductions for Nov. 20, 2009. Read more here. more

52-Week Highs

Here are some of the biggest stocks that made the 52-week high list on Nov. 20, 2009. more